Oral immunization with Lactococcus lactis-expressing EspB induces protective immune responses against Escherichia coli O157: H7 in a murine model of colonization

Vaccine

Volumn 32, Issue 31, 2014, Pages 3909-3916

  Ahmed, B ^a   Loos, M ^a   Vanrompay, D ^a   Cox, E ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Enterohemorrhagic Escherichia coli; EspB; Hemolytic uremic syndrome; Lactococcus lactis; Oral vaccination

Indexed keywords

BACTERIAL PROTEIN; ESCHERICHIA COLI VACCINE; ESPB PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; INTERLEUKIN 10; INTERLEUKIN 4; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; CYTOKINE; EAEB PROTEIN, E COLI; ESCHERICHIA COLI PROTEIN; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; CELL LYSATE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTEROHEMORRHAGIC ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LACTOCOCCUS LACTIS; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEYER PATCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; ESCHERICHIA COLI INFECTIONS; IMMUNOLOGY; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; TH1 TH2 BALANCE;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CYTOKINES; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FEMALE; IMMUNITY, MUCOSAL; LACTOCOCCUS LACTIS; MICE; MICE, INBRED BALB C; TH1-TH2 BALANCE;

EID: 84902011138     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.054     Document Type: Article

References (64)

1. Griffin P.M., Tauxe R.V. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev 1991, 13:60-98.
2. Trachtman H., Cnaan A., Christen E., Gibbs K., Zhao S., Acheson D.W., et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003, 290:1337-1344. (the journal of the American Medical Association).
3. Carter A.O., Borczyk A.A., Carlson J.A., Harvey B., Hockin J.C., Karmali M.A., et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987, 317:1496-1500.
4. Serna A., Boedeker E.C. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol 2008, 24:38-47.
5. Pavia A.T., Nichols C.R., Green D.P., Tauxe R.V., Mottice S., Greene K.D., et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990, 116:544-551.
6. Wong C.S., Jelacic S., Habeeb R.L., Watkins S.L., Tarr P.I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000, 342:1930-1936.
7. Wong C.S., Mooney J.C., Brandt J.R., Staples A.O., Jelacic S., Boster D.R., et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012, 55:33-41.
8. Hamada D. Cytoskeleton-modulating effectors of enteropathogenic and enterohemorrhagic Escherichia coli. FEBS J 2010, 277:2389.
9. Frankel G., Phillips A.D., Rosenshine I., Dougan G., Kaper J.B., Knutton S. Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Microbiol Biotechnol 1998, 30:911-921.
10. Kodama T., Akeda Y., Kono G., Takahashi A., Imura K., Iida T., et al. The EspB protein of enterohaemorrhagic Escherichia coli interacts directly with alpha-catenin. Cell Microbiol 2002, 4:213-222.
11. Knappstein S., Ide T., Schmidt M.A., Heusipp G. Alpha 1-antitrypsin binds to and interferes with functionality of EspB from atypical and typical enteropathogenic Escherichia coli strains. Infect Immun 2004, 72:4344-4350.
12. Iizumi Y., Sagara H., Kabe Y., Azuma M., Kume K., Ogawa M., et al. The enteropathogenic E. coli effector EspB facilitates microvillus effacing and antiphagocytosis by inhibiting myosin function. Cell Host Microbe. 2007, 2:383-392.
13. Asper D.J., Karmali M.A., Townsend H., Rogan D., Potter A.A. Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans. Clin Vaccine Immunol: CVI 2011, 18:1052-1057.
14. Li Y., Frey E., Mackenzie A.M., Finlay B.B. Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect Immun 2000, 68:5090-5095.
15. Karpman D., Bekassy Z.D., Sjogren A.C., Dubois M.S., Karmali M.A., Mascarenhas M., et al. Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections. Pediatr Nephrol 2002, 17:201-211.
16. Cataldi A., Yevsa T., Vilte D.A., Schulze K., Castro-Parodi M., Larzabal M., et al. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine 2008, 26:5662-5667.
17. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
18. Pavot V., Rochereau N., Genin C., Verrier B., Paul S. New insights in mucosal vaccine development. Vaccine 2012, 30:142-154.
19. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012, 12:592-605.
20. Berlec A., Ravnikar M., Strukelj B. Lactic acid bacteria as oral delivery systems for biomolecules. Pharmazie 2012, 67:891-898.
21. Tarahomjoo S. Development of vaccine delivery vehicles based on lactic acid bacteria. Mol Biotechnol 2012, 51:183-199.
22. Wells J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu Rev Food Sci Technol 2011, 2:423-445.
23. Ahmed B., Loos M., Vanrompay D., Cox E. Mucosal priming of the murine immune system against enterohemorrhagic Escherichia coli O157:H7 using Lactococcus lactis expressing the type III secretion system protein EspB. Vet Immunol Immunopathol 2013, 152:141-145.
24. Wells J.M., Wilson P.W., Lepage R.W.F. Improved cloning vectors and transformation procedure for Lactococcus lactis. J Appl Bacteriol 1993, 74:629-636.
25. Schotte L., Steidler L., Vandekerckhove J., Remaut E. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol 2000, 27:761-765.
26. Sebastiani S., Allavena P., Albanesi C., Nasorri F., Bianchi G., Traidl C., et al. Chemokine receptor expression and function in CD4(+) T lymphocytes with regulatory activity. J Immunol 2001, 166:996-1002.
27. Wadolkowski E.A., Burris J.A., Obrien A.D. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157-H7. Infect Immun 1990, 58:2438-2445.
28. Vandewalle K., Atefyekta M., Verdonck F., De Zutter L., Cox E. Rectal inoculation of sheep with E. coli O157:H7 results in persistent infection in the absence of a protective immune response. Vet Microbiol 2011, 147:376-382.
29. Neurath M.F., Finotto S., Glimcher L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002, 8:567-573.
30. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10:170-181.
31. Frees D., Ingmer H. ClpP participates in the degradation of misfolded protein in Lactococcus lactis. Microbiol Biotechnol 1999, 31:79-87.
32. Nilsson D., Lauridsen A.A., Tomoyasu T., Ogura T. A Lactococcus lactis gene encodes a membrane-protein with putative ATPase activity that is homologous to the essential Escherichia coli Ftsh gene-product. Microbiology-UK 1994, 140:2601-2610.
33. Koch B., Kilstrup M., Vogensen F.K., Hammer K. Induced levels of heat shock proteins in a DNAK mutant of Lactococcus lactis. J Bacteriol 1998, 180:3873-3881.
34. Bermudez-Humaran L.G., Langella P., Commissaire J., Gilbert S., Le Loir Y., L'Haridon R., et al. Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon in Lactococcus lactis. FEMS Microbiol Lett 2003, 224:307-313.
35. Ribeiro L.A., Azevedo V., Le Loir Y., Oliveira S.C., Dieye Y., Piard J.C., et al. Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ Microbiol 2002, 68:910-916.
36. Kimoto H., Nomura M., Kobayashi M., Mizumachi K., Okamoto T. Survival of lactococci during passage through mouse digestive tract. Can J Microbiol 2003, 49:707-711.
37. Drouault S., Corthier G., Ehrlich S.D., Renault P. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 1999, 65:4881-4886.
38. Steidler L., Hans W., Schotte L., Neirynck S., Obermeier F., Falk W., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
39. Huibregtse I.L., Snoeck V., de Creus A., Braat H., De Jong E.C., Van Deventer S.J., et al. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 2007, 133:517-528.
40. Hou J., Lu Y., Liu H.Y., Ma Y.J., Xing Y., Zhang Y., et al. Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice. Vaccine 2011, 29:4102-4109.
41. Yam K.K., Pouliot P., N'Diaye M.M., Fournier S., Olivier M., Cousineau B. Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. Vaccine 2008, 26:2689-2699.
42. Chatel J.M., Langella P., Adel-Patient K., Commissaire J., Wal J.M., Corthier G. Induction of mucosal immune response after intranasal or oral inoculation of mice with Lactococcus lactis producing bovine beta-lactoglobulin. Clin Diagn Lab Immunol 2001, 8:545-551.
43. Marelli B., Perez A.R., Banchio C., de Mendoza D., Magni C. Oral immunization with live Lactococcus lactis expressing rotavirus VP8* subunit induces specific immune response in mice. J Virol Methods 2011, 175:28-37.
44. Adel-Patient K., Ah-Leung S., Creminon C., Nouaille S., Chatel J.M., Langella P., et al. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 2005, 35:539-546.
45. Saez D., Fernandez P., Rivera A., Andrews E., Onate A. Oral immunization of mice with recombinant Lactococcus lactis expressing Cu, Zn superoxide dismutase of Brucella abortus triggers protective immunity. Vaccine 2012, 30:1283-1290.
46. Robinson K., Chamberlain L.M., Schofield K.M., Wells J.M., Le Page R.W. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997, 15:653-657.
47. Cho H.J., Shin H.J., Han I.K., Jung W.W., Kim Y.B., Sul D., et al. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine 2007, 25:8049-8057.
48. Pabst R., Rothkotter H.J. Structure and function of the gut mucosal immune system. Adv Exp Med Biol 2006, 579:1-14.
49. Cauchard S., Bermudez-Humaran L.G., Blugeon S., Laugier C., Langella P., Cauchard J. Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection. Vaccine 2011, 30:95-102.
50. Villena J., Medina M., Raya R., Alvarez S. Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection. Can J Microbiol 2008, 54:845-853.
51. Yamamoto M., Vancott J.L., Okahashi N., Marinaro M., Kiyono H., Fujihashi K., et al. The role of Th1 and Th2 cells for mucosal IgA responses. Ann NY Acad Sci 1996, 778:64-71.
52. Okahashi N., Yamamoto M., Vancott J.L., Chatfield S.N., Roberts M., Bluethmann H., et al. Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4(+) Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin a responses. Infect Immun 1996, 64:1516-1525.
53. Oliveira A.F., Cardoso S.A., Almeida F.B.D., de Oliveira L.L., Pitondo-Silva A., Soares S.G., et al. Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice. Microbiol Immunol 2012, 56:513-522.
54. Judge N.A., Mason H.S., O'Brien A.D. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infect Immun 2004, 72:168-175.
55. Garcia-Angulo V.A., Kalita A., Torres A.G. Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection. Vaccine 2013, 31:3229-3235.
56. Babiuk S., Asper D.J., Rogan D., Mutwiri G.K., Potter A.A. Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of Escherichia coli O157:H7 in mice. Microb Pathog 2008, 45:7-11.
57. Fan H.Y., Wang L., Luo J., Long B.G. Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins. Mol Biol Rep 2012, 39:989-997.
58. Vilte D.A., Larzabal M., Garbaccio S., Gammella M., Rabinovitz B.C., Elizondo A.M., et al. Reduced faecal shedding of Escherichia coli O157:H7 in cattle following systemic vaccination with gamma-intimin C-280 and EspB proteins. Vaccine 2011, 29:3962-3968.
59. Atefyekta M., Goddeeris B.M., Vanrompay D., Cox E. Immunization of sheep with a combination of intimin gamma, EspA and EspB decreases Escherichia coli O157:H7 shedding. Vet Immunol Immunopathol 2011, 140:42-46.
60. Bailey M. The immune system: differences between man, pigs, ruminants and mice. Front Immunol 2011, 10.3389/conf.fimmu.2011.01.00003.
61. Gasson M.J. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 1983, 154:1-9.
62. Kuipers O.P., de Ruyter P.G.G.A., Kleerebezem M., de Vos W.M. Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol 1998, 64:15-21.
63. Woodward M.J., Best A., Sprigings K.A., Pearson G.R., Skuse A.M., Wales A., et al. Non-toxigenic Escherichia coli O157:H7 strain NCTC12900 causes attaching-effacing lesions and eae-dependent persistence in weaned sheep. Int J Med Microbiol 2003, 293:299-308.
64. Mierau I., Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005, 68:705-717.